A reference work, not a recommendation to use: this profile describes mechanism and evidence and does not replace medical advice. The claims come from marketing and forums and are tested here, not endorsed.

Mechanism of action

Evidence map: Methylphenidate

Each line stands for a published finding; line style and color show where it comes from. The filter hides weaker evidence levels. Sources: see references.

The racemate of d- and l-threo-methylphenidate is used therapeutically. It inhibits the dopamine and noradrenaline transporters; according to cell, animal, and imaging data, the pharmacological effect comes overwhelmingly from d-methylphenidate [1]. In a PET study of 10 healthy adults, an oral dose occupied on average 60% of dopamine transporters and raised extracellular dopamine in the striatum; however, the degree of blockade did not predict the rise in dopamine [2].

The noradrenaline transporter is at least as important: in a placebo-controlled PET study of 11 healthy people, methylphenidate occupied the noradrenaline transporter in a dose-dependent manner and already at lower amounts than the dopamine transporter [3]. In rats, low amounts that improved attention and working memory raised noradrenaline and dopamine mainly in the prefrontal cortex and hardly in other brain regions [4].

Methylphenidate is well absorbed, reaches peak levels after about 2 hours, and has a half-life of 2 to 3 hours [5]. It is broken down mainly by carboxylesterase 1 in the liver to the inactive ritalinic acid, preferentially the l form, so that mainly d-methylphenidate circulates in the blood [6]. With alcohol, the same enzyme forms ethylphenidate; at the same time, the early concentration of d-methylphenidate rises, and euphoria is intensified [7].

Synaptik serves solely to explain biochemistry and pharmacology and is not medical advice or a recommendation to take anything.

Mechanism of action only. Schematic cross-section of a striatal dopaminergic synapse with a neighbouring noradrenergic terminal, plus an inset with a serotonergic terminal on the left; not to scale. Particle numbers, speeds and the bars of the live readout come from an illustrative model, not from measurements. Only for methylphenidate and modafinil does the share of blocked dopamine transporters (6 and 5 of 10) match a rounded PET occupancy, from two different studies; all other shares are illustrative.

DAT: 6 of 10 blocked by methylphenidate · NET blocked · dopamine lingers

DAT
inhibitedPET ≈ 60% (n = 10)
NET
inhibitedPET of NET; ED50 below DAT literature value
SERT
unchanged
synthesis (TH, AADC)
unchanged
dopamine in the cleft (model)
moredirection from PET study
Drug
View

dopamine  noradrenaline  serotonin  cAMP  drug  cross = transporter blocked

Methylphenidate blocks DAT and NET. An oral dose occupied on average 60% of striatal dopamine transporters in 10 healthy adults and raised extracellular dopamine; the degree of blockade did not predict the dopamine increase [14]. A placebo-controlled PET study of 11 healthy people measured only NET: half-maximal occupancy there came at lower amounts than a literature value for DAT cited for comparison [15]. The activity comes almost entirely from d-methylphenidate [16]. The blocked NETs (3 of 4) are illustrative.

Tap or focus a labelled part for a short explanation.

Also acting here, not drawn

  • Flmodafinil: DAT inhibition only from unpublished commissioned data (evidence level 0)
  • Saffron: at SERT only a computer simulation (docking), no measured binding or inhibition

What the figure shows, and how sure we are

Mechanism-of-action explainer only. Not medical advice, and no statement about benefit, risk, amount or use; each profile gives the legal status.

What was simplified. One terminal and one cleft stand for a striatal dopamine synapse; sizes, cleft width, numbers of vesicles, transporters and receptors, and all speeds are illustrative. Drugs are drawn on the outside of the transporter, not at their binding sites. The positions of TH, AADC and COMT are schematic. The occupancy values for methylphenidate and modafinil come from two studies with different amounts, brain regions and participants and are not directly comparable; the values for the other drugs come from cells, synaptosomes or animal studies. The numbers in [14] to [28] are in the Synaptik profiles of the drugs, where they were checked against the abstracts; [1] to [13] and [29] were checked on PubMed for this figure (26 Oct 2026), [2] bibliographically only.

If medicines or other substances are causing problems, a GP or a local addiction counselling service can help.

Targets

TargetTypeActionKey dataEvidence
Dopamine transporter (DAT)TransporterInhibitor≈ 60% occupancy in the striatum (human, PET) Human, non-randomised[1][2]
Noradrenaline transporter (NET)TransporterInhibitordose-dependent occupancy in the thalamus; higher potency than at the DAT (human, PET, placebo-controlled) Human, randomised[3]

Effect profile

Which signaling systems the compound affects according to current data. ↑ enhanced, ↓ dampened, ≈ modulated, ○ no effect; dots = evidence level.

  • Dopamine↑ · Extracellular dopamine raised in the striatum (human, PET, before-and-after comparison)[1][2]
  • Noradrenaline↑ · Noradrenaline transporter occupied in humans (PET, placebo-controlled); noradrenaline raised in the prefrontal cortex (rat)[3][4]
  • Serotoninno data
  • Acetylcholineno data
  • Glutamate · AMPAno data
  • Glutamate · NMDAno data
  • GABAno data
  • Histamineno data
  • Orexinno data
  • Adenosineno data
  • Opioidsno data
  • Melatoninno data
  • Neurotrophinsno data
  • Blood flowno data
  • Nitric oxideno data
  • Energy metabolismno data
  • Insulin · glucoseno data
  • Inflammation · oxidativeno data
  • Stress axisno data
  • Testosterone axisno data
  • Endocannabinoidsno data
  • Autophagy · senescenceno data
  • Immune systemno data
  • Lipid metabolismno data
  • Coagulation · fibrinolysisno data
  • Methylationno data

Human studies

  • PET of dopamine transporter and dopamine

    open-label, before-and-after comparison · healthy · n = 10 · Single dose

    Measured: DAT occupancy, extracellular dopamine

    Result: DAT occupancy 60 ± 11%, dopamine raised in the striatum; blockade and dopamine rise did not correlate.[2]

    Human, non-randomised

  • PET of the noradrenaline transporter

    single-blind, placebo-controlled, repeated measures · healthy · n = 11 · Single doses

    Measured: NET occupancy

    Result: Dose-dependent occupancy; half-maximal occupancy at a lower amount than at the DAT.[3]

    Human, randomised

  • Meta-analysis of cognition in healthy people (methylphenidate)

    meta-analysis of placebo-controlled studies (24 studies) · healthy, not sleep-deprived · Single dose

    Measured: Cognitive domains

    Result: Small overall effect (SMD 0.21), driven by recall (0.43), sustained attention (0.42), and inhibitory control (0.27).[11]

    Human, randomised

  • Meta-analysis of methylphenidate and amphetamine

    meta-analysis (48 studies) · healthy · n = 1409 · mostly single doses

    Measured: Inhibitory control, working memory, episodic memory

    Result: Small effects on inhibitory control and short-term memory, medium on delayed recall; signs of publication bias, overall effect probably modest.[12]

    Human, randomised

  • Network meta-analysis in ADHD

    network meta-analysis of double-blind RCTs (133 studies) · Patients: ADHD (children, adolescents, adults) · n = 8131 · around 12 weeks

    Measured: Core ADHD symptoms, dropouts due to side effects

    Result: Adults: SMD −0.49 versus placebo; more dropouts due to side effects (OR 2.39). n = all adults in the efficacy analysis across all compared agents.[13]

    Human, randomised

  • Long-term use and cardiovascular disease

    case-control study (Swedish registries) · Patients: ADHD, aged 6–64 years · n = 62060 · up to 14 years

    Measured: Newly occurring cardiovascular disease

    Result: Each year of ADHD medication use (not only methylphenidate) was associated with a 4% higher risk (AOR 1.04), mainly hypertension.[14]

    Human, non-randomised

  • Psychosis under methylphenidate vs. amphetamine

    cohort study with propensity score matching · Patients: ADHD, aged 13–25 years · n = 221846 · 143,286 person-years

    Measured: Newly diagnosed psychosis treated with an antipsychotic

    Result: 0.10% under methylphenidate, 0.21% under amphetamine (HR 1.65 for amphetamine).[15]

    Human, non-randomised

Risks and warnings

  • Abuse and dependence

    A controlled narcotic in Germany [8], Schedule II with high abuse potential in the US [10]; together with alcohol, euphoria is intensified [7].

    Human, non-randomised

  • Side effects

    Adults with ADHD dropped out of studies more often because of side effects under methylphenidate than under placebo (OR 2.39) [13].

    Human, randomised

  • Cardiovascular

    Long-term use of ADHD medication was associated with more cardiovascular disease in Swedish registry data, mainly hypertension; causality has not been proven [14].

    Human, non-randomised

  • Psychosis

    New-onset psychosis was rare in young people with ADHD, and less frequent under methylphenidate than under amphetamine (0.10% vs. 0.21%) [15].

    Human, non-randomised

Interactions

  • Alcohol: Carboxylesterase 1 forms ethylphenidate from methylphenidate and ethanol; the early d-methylphenidate concentration and euphoria rise [7].

Fact check: common claims

  • partly supported

    “Methylphenidate makes healthy people perform better when learning”

    Small laboratory improvements in recall, sustained attention, and inhibitory control [11][12]; effects on grades or academic success have not been studied, and publication bias is likely [12].

  • refuted

    “Methylphenidate acts only via dopamine”

    In humans, it occupies the noradrenaline transporter even at lower amounts than the dopamine transporter [3].

  • refuted

    “Methylphenidate is harmless because even children get it”

    More study dropouts due to side effects [13], signs of cardiovascular risks with long-term use [14], rare psychoses [15], and classification as a controlled narcotic [8].

Pharmacokinetics

Absorption
Well absorbed, peak levels after about 2 hours; crosses easily into the brain [5].
Half-life
2–3 hours; duration of action of the non-extended-release form 1–4 hours [5].
Metabolism
Mainly carboxylesterase 1 (liver) to the inactive ritalinic acid, preferentially l-methylphenidate [6]; with alcohol, formation of ethylphenidate [7].
Entry into the brain
Occupies dopamine and noradrenaline transporters in the human brain (PET) [2][3].

Legal status

Germany
Narcotic that may be prescribed: Annex III of the German Narcotics Act (BtMG) lists “Methylphenidat – Methyl[(RS;RS)(phenyl)(2-piperidyl)acetat]” [8][16]. Narcotics in Annex III may be prescribed only by physicians, dentists, or veterinarians and dispensed in a pharmacy only on presentation of the prescription (Section 13(1) and (2) BtMG) [17].
EU
Prescription-only medicinal product [9].
USA
Schedule II of the Controlled Substances Act (accepted medical use, high abuse potential) [10].

Open questions

  • In healthy people, does methylphenidate improve real-world performance (exams, work) or mainly the subjective feeling of drive?
  • How large is the cardiovascular risk specifically for methylphenidate, separate from other ADHD medications?
  • What share do noradrenaline and dopamine each have in the effect on attention?

References

  1. Markowitz JS, Patrick KS. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol. 2008;28(3 Suppl 2):S54–61. doi:10.1097/JCP.0b013e3181733560 · PubMed
  2. Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, Maynard L, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 2002;43(3):181–7. doi:10.1002/syn.10038 · PubMed
  3. Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van Dyck CH, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry. 2010;68(9):854–60. doi:10.1016/j.biopsych.2010.06.017 · PubMed
  4. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006;60(10):1111–20. doi:10.1016/j.biopsych.2006.04.022 · PubMed
  5. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet. 1999;37(6):457–70. doi:10.2165/00003088-199937060-00002 · PubMed
  6. Stevens T, Sangkuhl K, Brown JT, Altman RB, Klein TE. PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics. Pharmacogenet Genomics. 2019;29(6):136–54. doi:10.1097/FPC.0000000000000376 · PubMed
  7. Patrick KS, Corbin TR, Murphy CE. Ethylphenidate as a selective dopaminergic agonist and methylphenidate-ethanol transesterification biomarker. J Pharm Sci. 2014;103(12):3834–42. doi:10.1002/jps.24202 · PubMed
  8. Dominik P, Waßmer MP, Soyka M, Franke AG. Stimulant abuse as a coping strategy – forensic and criminal consequences of stimulant abuse for neuroenhancement. Front Public Health. 2022;10:1028654. doi:10.3389/fpubh.2022.1028654 · PubMed
  9. Vanhee C, Deconinck E, George M, Hansen A, Hackl A, Wollein U, et al. The occurrence of illicit smart drugs or nootropics in Europe and Australia and their associated dangers: results from a market surveillance study by 12 official medicines control laboratories. J Xenobiot. 2025;15(3):88. doi:10.3390/jox15030088 · PubMed
  10. Keeton VF. Pharmaceutical supply chains: a structural determinant of health for children with ADHD. J Pediatr Health Care. 2025;39(2):297–302. doi:10.1016/j.pedhc.2024.11.001 · PubMed
  11. Roberts CA, Jones A, Sumnall H, Gage SH, Montgomery C. How effective are pharmaceuticals for cognitive enhancement in healthy adults? A series of meta-analyses of cognitive performance during acute administration of modafinil, methylphenidate and D-amphetamine. Eur Neuropsychopharmacol. 2020;38:40–62. doi:10.1016/j.euroneuro.2020.07.002 · PubMed
  12. Ilieva IP, Hook CJ, Farah MJ. Prescription stimulants' effects on healthy inhibitory control, working memory, and episodic memory: a meta-analysis. J Cogn Neurosci. 2015;27(6):1069–89. doi:10.1162/jocn_a_00776 · PubMed
  13. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–38. doi:10.1016/S2215-0366(18)30269-4 · PubMed
  14. Zhang L, Li L, Andell P, Garcia-Argibay M, Quinn PD, D'Onofrio BM, et al. Attention-deficit/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry. 2024;81(2):178–87. doi:10.1001/jamapsychiatry.2023.4294 · PubMed
  15. Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380(12):1128–38. doi:10.1056/NEJMoa1813751 · PubMed
  16. Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz – BtMG), Anlage III (zu § 1 Abs. 1): verkehrsfähige und verschreibungsfähige Betäubungsmittel, Eintrag „Methylphenidat – Methyl[(RS;RS)(phenyl)(2-piperidyl)acetat]“. Stand: zuletzt geändert durch Art. 1 V v. 19.5.2026 (BGBl. 2026 I Nr. 150); laut Standhinweis ist die Änderung durch Art. 8 G v. 26.6.2026 (BGBl. 2026 I Nr. 195) textlich nachgewiesen, dokumentarisch noch nicht abschließend bearbeitet. Bundesministerium der Justiz [Internet]. Abgerufen am 26.10.2026. Verfügbar unter: https://www.gesetze-im-internet.de/btmg_1981/anlage_iii.html
  17. Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz – BtMG), § 13 Verschreibung und Abgabe auf Verschreibung. Bundesministerium der Justiz [Internet]. Abgerufen am 26.10.2026. Verfügbar unter: https://www.gesetze-im-internet.de/btmg_1981/__13.html
How this profile was checked

Last reviewed: 2026-10-26. All sources with a DOI or PMID were resolved automatically via Crossref or doi.org and PubMed.

Translated from the German profile (version of 2026-10-26); translation checked on 2026-10-26.

Checked

  • October 26, 2026 (decision n015, audit report E-20 question 14): `rx_referenz` set, `kategorie` remains Nootropikum. BtMG Annex III retrieved in the statutory text (“gesetze-im-internet.de”, status: last amended by Art. 1 of the Ordinance of May 19, 2026, BGBl. 2026 I No. 150, with a status note on Art. 8 of the Act of June 26, 2026): entry “Methylphenidat – Methyl[(RS;RS)(phenyl)(2-piperidyl)acetat]” [16]; Section 13(1) and (2) BtMG read (prescription only by physicians, dentists, or veterinarians; dispensing in the pharmacy only on presentation of the prescription) [17]. The prescription requirement in Germany is thus documented at the primary source; until now, status.deutschland rested only on a review [8]. Methylphenidate is not listed in AMVV Annex 1 (full-text search October 26, 2026) because narcotics are subject to the BtMG.
  • All 15 DOIs resolved via Crossref and all PMIDs via PubMed with tools/pruefe_profile.py.
  • Abstracts: d-MPH as the active component, DAT and NET [1]; n = 10, DAT 60 ± 11%, raclopride −16%, no correlation [2]; n = 11, single-blind with placebo, NET ED50 below DAT ED50 [3]; prefrontal preference in rats [4]; t½ 2–3 h, Tmax ≈ 2 h, duration of action 1–4 h [5]; ethylphenidate, euphoria [7]; SMD 0.21/0.43/0.42/0.27 in 24 studies [11]; 48 studies, 1409 participants, publication bias [12]; adults SMD −0.49, OR 2.39, n = 8131 [13]; AOR 1.04 per year, cases 10,388 and controls 51,672 [14]; 221,846 matched, 0.10% vs. 0.21%, HR 1.65 [15].
  • In the full text: CES1 → ritalinic acid, l form preferred [6]; methylphenidate in Annex III, modafinil not in the Narcotics Act [8]; “Prescription medicine in the EU and Australia” [9]; stimulants as Schedule II [10].
  • ClinicalTrials.gov: 588 entries for methylphenidate (October 23, 2026).

Not verified

  • According to their abstracts, the two dopamine PET studies from the Volkow group (2001, 2002) are before-and-after comparisons without a mentioned placebo condition; hence evidence level 3 for the dopamine mechanism in humans.
  • The cardiovascular data [14] apply to ADHD medications as a whole, not specifically to methylphenidate.
  • Clinical interaction studies with alcohol captured only via the review [7].

No dosages, no sources of supply. This information does not replace medical advice.

Spotted an error or missing something?

Request a compound, suggest an improvement or report an error. Every message is read.

Type of message

The website stores nothing. The button opens your email app with a pre-filled message.